Joseph Gathe, Jr., MD

Medical Director
Therapeutic Concepts
Houston, TX

Disclosure: Abbott: Scientific Research Study Investigator
AbbVie: Grant/Research Support, Other Financial or Material Support, Consultant or speaker in company-supported conferences
Avexa: Scientific Research Study Investigator
Boehringer Ingelheim: Grant/Research Support, Scientific Research Study Investigator
Bristol-Myers Squibb: Grant/Research Support, Other Financial or Material Support, Consultant or speaker in company-supported conferences
Gilead: Grant/Research Support, Scientific Research Study Investigator, Consultant or speaker in company-supported conferences
GlaxoSmithKline: Grant/Research Support, Scientific Research Study Investigator, Other Financial or Material Support, Consultant or speaker in company-supported conferences
Hiesped: Scientific Research Study Investigator
Janssen: Grant/Research Support, Scientific Research Study Investigator, Consultant or speaker in company-supported conferences
Merck: Grant/Research Support, Scientific Research Study Investigator, Consultant or speaker in company-supported conferences
Parexel: Scientific Research Study Investigator
Pfizer: Grant/Research Support, Scientific Research Study Investigator
Roche: Scientific Research Study Investigator
ViiV: Grant/Research Support, Other Financial or Material Support, Consultant or speaker in company-supported conferences

Presentation(s):

• 887 - High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) With the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial

  Thursday, October 3
  4:15 PM – 4:30 PM